• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Somatuline Depot (lanreotide acetate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Somatuline Depot (lanreotide acetate)

  • Profile

Profile

Contact Information

Contact: Ipsen Biopharmaceuticals
Website: http://www.somatulinedepot.com/

Currently Enrolling Trials

    Show More

    General Information

    Somatuline Depot (lanreotide acetate) is an injectable, sustained-release formulation of lanreotide, an octapeptide somatostatin analog that inhibits Insulin-like growth factor-1 (IGF-1) and growth hormone (GH).

    Somatuline is specifically indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.

    Mechanism of Action

    Somatuline Depot (lanreotide acetate) is an injectable, sustained-release formulation of lanreotide, an octapeptide somatostatin analog that inhibits Insulin-like growth factor-1 (IGF-1). Lanreotide has a high affinity for human somatostatin receptors (SSTR) 2 and 5 and a reduced binding affinity for human SSTR1, 3 and 4. Activity at human SSTR 2 and 5 is the primary mechanism believed responsible for growth hormone inhibition. Like somatostatin, lanreotide is an inhibitor of various endocrine, neuroendocrine, exocrine and paracrine functions.

    Side Effects

    Adverse events associated with the use of Somatuline Depot may include, but are not limited to, the following:

    • diarrhea
    • abdominal pain
    • nausea
    • constipation
    • flatulence
    • vomiting
    • loose stools
    • cholelithiasis
    • injection site reactions

    Dosing/Administration

    Somatuline is supplied in strengths of 60 mg, 90 mg and 120 mg designed for subcutaneous injection. The recommended initial dose of the drug in subjects with moderate and severe renal or moderate and severe hepatic impairment is 60 mg at four-week intervals for three months followed by dose adjustment as described below. The recommended initial dose of the drug for all other subjects is 90 mg at four-week intervals for three months. After three months the dosage may be adjusted as follows:

    • GH >1 to = 2.5 ng/mL, IGF-1 normal and clinical symptoms controlled: maintain Somatuline Depot dose at 90 mg every four weeks.
    • GH > 2.5 ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled, increase Somatuline Depot dose to 120 mg every four weeks.
    • GH = 1 ng/mL, IGF-1 normal and clinical symptoms controlled: reduce Somatuline Depot dose to 60 mg every four weeks.

    Thereafter the dose should be adjusted according to the response of the patient as measured by reduction in serum GH and /or IGF-1 levels; and/or changes in symptoms of acromegaly.

    Clinical Trial Results

    FDA approval of Somatuline Depot was based on the results of two clinical studies.
    Study One
    This one-year study consisted of a four-week, double-blind, placebo-controlled phase, a 16-week single-blind, fixed-dose phase and a 32-week open-label dose-titration phase. All the subjects who had received previous treatment with a somatostatin analog or a dopaminergic agonist were required to undergo a 12-week washout period. In the initial phase, 108 subjects were randomly allocated to receive a single deep subcutaneous injection of Somatuline Depot 60, 90 or 120 mg or placebo. Four weeks later, they entered a fixed dose phase where they received four injections of Somatuline Depot; this was completed by 105 subjects. This was followed by a dose-titration phase of eight injections for a total of 13 injections over 52 weeks (including the placebo phase). Injections were given at four-week intervals. The dose was titrated twice (every fourth injection), as needed. This phase was completed by 99 subjects. In the double-blind phase of the study, a total of 63 percent of the lanreotide treated subjects had a > 50 percent decrease in mean GH from baseline to week 4 including 52 percent, 44 percent and 90 percent of patients in the 60, 90 and 120 mg groups, respectively, compared to placebo (0 percent). In the fixed-dose phase at week 16, 72 percent of all lanreotide-treated subjects had a decrease from baseline in mean GH of > 50 percent including 68 percent, 64 percent and 84 percent of subjects in the 60, 90 and 120 mg lanreotide treatment groups, respectively. Efficacy achieved in the first 16 weeks was maintained throughout the trial duration.

    Study Two
    This 48-week, open-label, uncontrolled study enrolled 63 subjects with IGF-1 concentration = 1.3 times the upper limit of normal age range; of whom 57 completed treatment. Any subject who had received prior treatment with a somatostatin analog or dopaminergic agonist underwent a washout period of up to three months. The subjects entered a four-month fixed dose phase where they received four deep 90 mg subcutaneous injections of Somatuline at four-week intervals. They then entered into a dose-titration phase where the dose of Somatuline was adjusted according to GH and IGF-1 levels at the beginning of the dose titration phase and, if necessary, after another four injections. The subjects were titrated up to the maximum dose of 120 mg and could not titrate down again. After 48 weeks, 43 percent of the subjects achieved normal age-adjusted IGF-1 concentrations. The mean IGF-1 concentrations after treatment were 1.3 ± 0.7 times the upper limit of normal compared to 2.5 ± 1.1 times the upper limit of normal at baseline. The proportion of subjects with mean GH concentrations of < 2.5 ng/mL increased significantly from 35 percent to 77 percent after the fixed-dose phase and 85 percent at the end of the study. At the end of treatment 38 percent of the subjects had both normal IGF-1 concentrations and a GH concentration of less than or equal to 2.5 ng/mL and 27 percent had both normal IGF-1 concentrations and a GH concentration of <1 ng/mL.

    Approval Date: 2007-08-01
    Company Name: Beaufour Ipsen
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing